Bibliography

Below are the citations for the articles incorporated into CaP Calculator®. Additionally, we provide the Entrez PubMed ID (PMID) for each article so you can obtain the full article if you are interested in learning more detail.

Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW.  A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.  J Urol 2003;170:1798-1803
PMID: 14532779

Cheng L, Slezak J, Berhstralh EJ, Myers RP, Zincke H, Bostwick DG.  Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy.  J Clin Oncol 2000;18:2862-2868
PMID: 10920134

Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.  J Urol. 1998;159:2023-2029
PMID: 9598511

Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.  J Urol 2005;173:1938-1942
PMID: 15879786

D'Amico AV, Whittington R, Malkowicz SB, Schulz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.  JAMA 1998;280:969-974
PMID: 9749478

Diaz A, Roach M 3rd, Marquez C, Coleman L, Pickett B, Wolfe JS, Carroll P, Narayan P.  Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer.  Int J Radiat Oncol Biol Phys. 1994;30:323-329
PMID: 7523343

Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Aronson WJ; Search Database Study Group.  Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.  J Urol 2004;171:2215-2220
PMID: 15126788

Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW.  Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.  Urology 2003;61:589-595
PMID: 12639653

Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer.  J Clin Oncol. 2000;18:3352-3359 
PMID: 11013275

Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA.  Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.  J Clin Oncol. 2003;21:4568-4571 
PMID: 14673043

Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, Scardino PT. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393-399
PMID: 11549487

Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL.  Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.  Int J Radiat Oncol Biol Phys 2003;57:915-928
PMID: 14575822

Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007 Jun;69(6):1095-101.
PMID: 17572194

Naya Y, Babaian RJ.  The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.  J Urol. 2003;170:2306-2310
PMID: 14634402

Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451
PMID: 9145716

Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006 May 17;98(10):715-7.
PMID: 16705126

Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451
PMID: 9145716

Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL.  Increasing external beam dose for T1-2 prostate cancer: effect on risk groups.  Int J Radiat Oncol Biol Phys 2006;65: 975-981
PMID: 16750319